The shadow of generic rivalry has consistently loomed around copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the prospects of related pharmaceutical ventures. While early periods saw significant gains, the patent expiration has allowed the way for cheaper alternatives, likely reducing revenue and presenting a significant danger